Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.

GlobeNewsWire • Jun 4, 2026

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,172,414 shares of the Company's common stock originally issued by the Company on November 26, 2025, having an original exercise price of $3.50 per share, at a reduced exercise price of $1.73 per share. The closing of the warrant exercise transaction is expected to occur on or about May 29, 2025, subject to satisfaction of customary closing conditions.

GlobeNewsWire • May 29, 2026

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)

GlobeNewsWire • May 14, 2026

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, Ireland. Updates include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.

GlobeNewsWire • May 6, 2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.

GlobeNewsWire • Apr 29, 2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of potentially registrational study in Q4 2026 Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has achieved a key milestone in the development of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma (“rrMM”).

GlobeNewsWire • Apr 22, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D.

GlobeNewsWire • Apr 14, 2026

New Strong Buy Stocks for April 10th

ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.

Zacks Investment Research • Apr 10, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif.

GlobeNewsWire • Mar 30, 2026

Tempest Therapeutics Announces Up To $6 Million Private Placement

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 925,927 shares of common stock and short-term series B warrants to purchase up to 925,927 shares of common stock, at a combined purchase price of $2.16 per share of common stock (or $2.159 per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement.

GlobeNewsWire • Mar 23, 2026